Study Evaluating Hemay022 in Combination With Endocrine Therapy In Subjects With ER Positive and HER2 Positive Advanced Breast Cancer

  • days left to enroll
  • participants needed
  • sponsor
    Tianjin Hemay Pharmaceutical Co.,Ltd
Updated on 11 May 2021
endocrine therapy
hormone therapy
advanced breast cancer


The purpose of this study is to evaluate the safety and tolerability of Hemay022 combined with endocrine therapy in the treatment of ER and HER2-positive metastatic or advanced breast cancer, and to establish OTR (best tolerated regimen). The second purpose of this study is to evaluate the pharmacokinetics and efficacy of Hemay022 in combination with exemestane, and the safety of Hemay022 in combination with letrozole or fulvestrant.

The research will be divided into two parts. In the first part, 15 to 24 subjects will be enrolled to determine the safety and tolerability of combining Hemay022 with exemestane in patients with HER2-positive advanced breast cancer. The second part will enroll about 24-36 other subjects with ER and HER2-positive advanced breast cancer to better determine the tolerability and preliminary efficacy of Hemay022.

Condition Breast Cancer, Breast Cancer, Breast Cancer Diagnosis, breast carcinoma, cancer, breast
Treatment exemestane, Hemay022, exemestane or letrozole or fulvestrant, Hemay022+exemestane, Hemay022+letrozole, Hemay022+ fulvestrant
Clinical Study IdentifierNCT03308201
SponsorTianjin Hemay Pharmaceutical Co.,Ltd
Last Modified on11 May 2021


Yes No Not Sure

Inclusion Criteria

Breast cancer subjects diagnosed by tumor histology
Objective evidence shows that patients with metastasis or relapse who cannot be cured by standard treatment
ER positive (1%) and HER2 over-expression (immunohistochemical IHC test 3+ and/or in situ hybridization ISH test positive), Post-menopausal female subjects who are suitable for exemestane as endocrine therapy ; Remarks: The expansion period is planned to include 6 subjects combined with letrozole and 6 subjects combined with fulvestrant in the 400mg dose group. Therefore, for this part of the subjects, the expansion period is included " Post-menopausal female subjects who are suitable for letrozole or fulvestrant as endocrine therapy
Postmenopausal is defined as meeting any one of the following four conditions
Past bilateral oophorectomy
Age 60 years old
Age <60 years old, natural menopause 12 months, in the past 1 year without chemotherapy, tamoxifen, toremifene or ovarian castration, the level of follicle stimulating hormone (FSH) and estradiol Within the postmenopausal range (use the reference range of the local laboratory)
Patients younger than 60 years old who are taking tamoxifen or toremifene, their FSH and estradiol levels are within the postmenopausal range (use the reference range of the local laboratory); Remarks: Premenopausal or perimenopausal women who do not meet the above-mentioned menopausal criteria can also be included in this study, but they must also receive zoladex ovarian suppression therapy. Ovarian suppression therapy has been started at least 14 days before the start of this program, and Must be continued during the treatment plan; For subjects whose postmenopausal status is difficult to judge, the investigator and medical personnel of the sponsor will determine whether to enter the group after discussion
At least one evaluable tumor lesion (according to RECIST1.1) or only bone metastases
ECOG Performance Status of 0-1
The estimated survival time is more than 3 months
Bone marrow function meets: ANC1.5109/L, HB90 g/L (allowed for blood transfusion), PLT80109/L. Liver function satisfies: ALT2.5ULN, AST2.5ULN, TBIL1.5ULN (ALT5ULN, AST5ULN in patients with liver metastases); renal function satisfies: blood creatinine 1.5ULN
Subjects must give informed consent to the study before the study entry and voluntarily sign a written informed consent form
The subject can communicate well with the investigator and can complete the research in accordance with the research regulations

Exclusion Criteria

There are life-threatening visceral metastases, any central nervous system metastases or leptomeninges carcinomatosis
Have received exemestane for breast cancer treatment (Note: If exemestane was previously used in the adjuvant treatment stage, and the drug has been stopped for 12 months before this enrollment, you can join the group); Remarks: For subjects who have been combined with letrozole in the extended phase, if they have received letrozole to treat breast cancer, they need to be excluded (if letrozole is used in the adjuvant treatment phase, and the drug has been stopped for 12 months before this enrollment , You can be included in the group); for subjects who have been combined with fulvestrant in the extended phase, if they have received fulvestrant for breast cancer, they need to be excluded
The first-line endocrine therapy was used in the late stage, and the drug was stopped for less than 4 weeks
Have received chemotherapy for advanced breast cancer> 2 lines (the subjects who have used chemotherapy drugs must have stopped the chemotherapy drugs for 4 weeks before being enrolled in this study)
Patients who are known to have a history of allergies to Hemay022, exemestane or similar drugs (Note: For patients who are planning to combine letrozole or fulvestrant, if they are known to be allergic to letrozole or fulvestrant History cannot be included in this study)
Have received radiotherapy within 4 weeks prior to study
Patients with parenteral nutrition; malabsorption syndrome; or any condition possibly affecting drug absorption or inability to tolerate oral medications
Complicated with 2 grade diarrhea or 2 grade nausea condition
Use of any drug that inhibits or induces hepatic metabolism of Hemay022 within 2 weeks prior to study and entire study duration, for example CYP3A4 strong inhibitors or strong inducers
Active infection (ie, requiring intravenous antibiotic or antiviral agent)
Uncontrolled hypertension (systolic blood pressure> 150 mmHg, diastolic blood pressure> 100 mmHg after antihypertensive treatment)
Left ventricular ejection fraction (LVEF) <50 as measured by echocardiogram or MUGA scan
Significant heart diseases, including ischemic heart disease (NYHA III-IV), history of myocardial infarction or uncontrolled angina within 6 months, occurrence congestive heart failure within 3 months
Positive blood for human immunodeficiency virus (HIV antibody), hepatitis B virus surface antigen, or hepatitis C virus antibody at screening
Arrhythmias requiring treatment , including atrial fibrillation, supraventricular tachycardia ,ventricular tachycardia, ventricular fibrillation, or patients with coronary heart disease have symptoms requiring medicine treatment, myocardial infarction within 1 year, congestive heart failure (CHF)
Confirmed ECG abnormalities, including QTc (heart rate corrected according to Bazett formula or Fridericia formula) prolongation (450msec), QRS> 120ms
History of hemorrhagic or thrombus events within 6 months, such as cerebrovascular accident (including transient ischemic attack), pulmonary embolism, spontaneous tumor bleeding
Have received other clinical trial treatments or other targeted drugs within 4 weeks before the study
Major surgery or injury less than 4 weeks before the study
Other chemotherapy, targeted therapy, hormone therapy, immunotherapy, radiotherapy (except symptomatic local radiotherapy) during the research
Serious psychogenic illness
Any other malignant cancer within 5 years with the exception of adequately treated cervical cancer in situ or basal and squamous cutaneous cell carcinomas
Subjects could not complete the study due to other reasons
History of alcohol or drug abuse
Evidence of significant medical illness or abnormal laboratory finding that would make the subject inappropriate for this study by the investigator's judgment
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note